

## **Helix BioMedix Closes \$2.37 Million Financing**

*May 04, 2004 - Bothell, Washington*

Helix BioMedix, Inc. (HXBM.OB) today announced that on May 3 it conducted the final closing under a private placement equity financing. The total amount raised in this financing was \$2.37 million, which includes \$1.1 million from the initial closing, referenced in the company's release dated March 22, 2004.

In this financing the company sold units, each of which were comprised of 50,000 shares of common stock and a warrant to purchase 17,500 shares of common stock. Units were priced at \$100,000 which equates to \$2.00 per share of stock and 0.35 warrant share. The company will issue 1,184,000 shares of common stock and associated warrants to purchase an additional 414,400 shares of common stock.

"We are very pleased to close this round of financing," stated David Kirske, Vice President, Finance and Administration. "The \$2.37 million gross proceeds, together with our existing cash, ensure that the company will continue to execute its current business plan well into FY2005."

Additionally, the company announced that at its annual stockholder meeting, held April 30, 2004, stockholders elected Dr. Randall L-W. Caudill to serve as a Class I Director until the annual meeting in 2007, and ratified the appointment of KPMG LLP as the company's independent auditor.

### **About Helix BioMedix:**

Helix BioMedix, Inc. is an early-stage biotechnology company that has a portfolio of issued patents which covers six distinct classes of peptides, covering over 100,000 unique peptide sequences. The company's mission is to become the industry leader in developing and commercializing small proteins known as bioactive peptides. The antimicrobial and wound healing properties of these peptides qualify them for inclusion in a wide range of both pharmaceutical and consumer products. The company is currently focused on the development of selected peptides as pharmaceutical agents for use in treating sexually transmitted diseases and in wound healing. Non-pharmaceutical applications being pursued by Helix BioMedix include adjuvants for cosmetics/cosmeceuticals, personal care, plant health, animal health and wide- spectrum biocides. More information about the company and its proprietary peptides can be found on the company's website at [www.helixbiomedix.com](http://www.helixbiomedix.com).

Statements made in this press release relating to Helix BioMedix's future growth potential are forward-looking and actual results could differ materially. Among other things, Helix BioMedix's future growth potential could be impacted by a number of factors, including the company's ability to enter into revenue generating licenses and its ability to raise additional capital.